综述

脑微出血的临床意义及其伴心房颤动时的抗凝治疗决策进展

展开
  • 北京医院保健医疗部神经内科 国家老年医学中心 中国医学科学院老年医学研究院,北京 100730

收稿日期: 2019-11-28

  网络出版日期: 2022-07-14

本文引用格式

武冬冬, 胡夏生, 刘银红, 蒋景文 . 脑微出血的临床意义及其伴心房颤动时的抗凝治疗决策进展[J]. 诊断学理论与实践, 2020 , 19(05) : 534 -539 . DOI: 10.16150/j.1671-2870.2020.05.018

参考文献

[1] Offenbacher H, Fazekas F, Schmidt R, et al. MR of cerebral abnormalities concomitant with primary intracerebral hematomas[J]. Am J Neuroradiol, 1996, 17(3):573-578.
[2] Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intra-cerebral hemorrhage: evidence of microangiopathy-related microbleeds[J]. Am J Neuroradiol, 1999, 20(4):637-642.
[3] Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study[J]. Stroke, 2010, 41(10 Suppl):S103-S106.
[4] Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting[J]. Brain, 2007, 130(Pt 8):1988-2003.
[5] Fisher M. Cerebral microbleeds: where are we now?[J]. Neurology, 2014, 83(15):1304-1305.
[6] Cheng AL, Batool S, McCreary CR, et al. Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds[J]. Stroke, 2013, 44(10):2782-2786.
[7] Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation[J]. J Am Coll Cardiol, 2004, 43(6):929-935.
[8] Saito T, Kawamura Y, Tanabe Y, et al. Cerebral microbleeds and asymptomatic cerebral infarctions in patients with atrial fibrillation[J]. J Stroke Cerebrovasc Dis, 2014, 23(6):1616-1622.
[9] European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2010, 31(19):2369-2429.
[10] Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal[J]. Stroke, 2012, 43(7):1812-1817.
[11] Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation[J]. Lancet Neurol, 2009, 8(2):165-174.
[12] Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies[J]. Stroke, 2010, 41(6):1222-1228.
[13] Jeon SB, Kang DW, Cho AH, et al. Initial microbleeds at MR imaging can predict recurrent intracerebral hemorrhage[J]. J Neurol, 2007, 254(4):508-512.
[14] Imaizumi T, Inamura S, Nomura T. Contribution of deep microbleeds to stroke recurrence: differences between patients with past deep intracerebral hemorrhages and lacunar infarctions[J]. J Stroke Cerebrovasc Dis, 2015, 24(8):1855-1864.
[15] Vermeer SE, Algra A, Franke CL, et al. Long-term prognosis after recovery from primary intracerebral hemorrhage[J]. Neurology, 2002, 59(2):205-209.
[16] Charidimou A, Kakar P, Fox Z, et al. Cerebral micro-bleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts[J]. Stroke, 2013, 44(4):995-1001.
[17] Wilson D, Charidimou A, Ambler G, et al. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a meta-analysis[J]. Neurology, 2016, 87(14):1501-1510.
[18] Akoudad S, Portegies ML, Koudstaal PJ, et al. Cerebral microbleeds are associated with an increased risk of stroke: the rotterdam study[J]. Circulation, 2015, 132(6):509-516.
[19] Charidimou A, Karayiannis C, Song TJ, et al. Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF[J]. Neurology, 2017, 89(23):2317-2326.
[20] Song TJ, Kim J, Song D, et al. Association of cerebral microbleeds with mortality in stroke patients having atrial fibrillation[J]. Neurology, 2014, 83(15):1308-1315.
[21] Eckman MH, Wong LK, Soo YO, et al. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?[J]. Stroke, 2008, 39(12):3308-3315.
[22] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151.
[23] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11):981-992.
[24] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10):883-891.
[25] Cervera A, Amaro S, Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage[J]. J Neurol, 2012, 259(2):212-224.
[26] Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis[J]. Stroke, 2003, 34(7):1710-1716.
[27] Greenberg SM, Eng JA, Ning M, et al. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage[J]. Stroke, 2004, 35(6):1415-1420.
[28] Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoa-gulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intra-cerebral hemorrhage[J]. JAMA, 2015, 313(8):824-836.
[29] Passero S, Burgalassi L, D'Andrea P, et al. Recurrence of bleeding in patients with primary intracerebral hemorrhage[J]. Stroke, 1995, 26(7):1189-1192.
[30] Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46(7):2032-2060.
[31] Wilson D, Jäger HR, Werring DJ. Anticoagulation for atrial fibrillation in patients with cerebral microbleeds[J]. Curr Atheroscler Rep, 2015, 17(8):47.
[32] Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review[J]. Neurology, 2007, 69(6):546-554.
[33] Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas[J]. Stroke, 2005, 36(7):1588-1593.
[34] Song TJ, Kim J, Lee HS, et al. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation[J]. Eur J Neurol, 2013, 20(3):502-508.
[35] Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study[J]. Lancet Neurol, 2018, 17(6):539-547.
[36] Soo Y, Abrigo JM, Leung KT, et al. Risk of intracerebral whaemorrhage in Chinese patients with atrial fibrillation on warfarin with cerebral microbleeds: the IPAAC-warfarin study[J]. J Neurol Neurosurg Psychiatry, 2019, 90(4):428-435.
[37] Wilson D, Charidimou A, Ambler G, et al. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a meta-analysis[J]. Neurology, 2016, 87(14):1501-1510.
[38] Selim M, Diener HC. Atrial fibrillation and microbleeds[J]. Stroke, 2017, 48(10):2660-2664.
[39] Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis[J]. Europace, 2011, 13(5):723-746.
[40] Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation[J]. Circulation, 2007, 115(21):2689-2696.
[41] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey[J]. Chest, 2010, 138(5):1093-1100.
[42] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921):955-962.
[43] Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage[J]. Neurology, 2009, 72(2):171-176.
[44] Saito T, Kawamura Y, Sato N, et al. Non-vitamin K anta-gonist oral anticoagulants do not increase cerebral micro-bleeds[J]. J Stroke Cerebrovasc Dis, 2015, 24(6):1373-1377.
[45] Fisher M. MRI screening for chronic anticoagulation in atrial fibrillation[J]. Front Neurol, 2013, 4:137.
[46] Wang Z, Soo YO, Mok VC. Cerebral microbleeds: is antithrombotic therapy safe to administer?[J]. Stroke, 2014, 45(9):2811-2817.
[47] Smith EE, Saposnik G, Biessels GJ, et al. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2017, 48:e44-e71.
[48] Microbleeds International Collaborative Network. Worldwide collaboration in the Microbleeds International Collaborative Network[J]. Lancet Neurol, 2016, 15(11):1113-1114.
[49] Charidimou A, Soo Y, Heo JH, et al. A call for researchers to join the META-MICROBLEEDS Consortium[J]. Lancet Neurol, 2016, 15(9):900.
文章导航

/